{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":3,"sponsored":0,"items":[{"id":"n_5pn2pbf6op55kmker4da","seq":1746781,"kind":"article","title":"AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69750148-aavantgarde-presents-encouraging-clinical-data-from-aavb-081-and-preclinical-data-supporting-aavb-039-at-euretina-2026-399.htm","published":"2026-10-05T01:10:00Z","seen":"2026-10-05T02:22:07Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","health","science","politics"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q140876515","name":"European Society of Retina Specialists","type":"event"}],"story":"st_rm4huhuuz7rwcuvuikza","category":"health","category_p":0.42,"sentiment":"positive","tone":0.05,"political":0.05},{"id":"n_mi2dpgu6pb5rfsflmweq","seq":1101808,"kind":"article","title":"Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions","url":"https://www.timesargus.com/news/business/genentech-presents-new-data-at-euretina-highlighting-vabysmo-s-real-world-effectiveness-and-safety-across/article_0eb0b392-dff9-53d6-a36d-030cbc86475d.html","summary":"SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 1, 2026--","published":"2026-10-01T06:01:56Z","seen":"2026-10-01T09:49:09Z","lang":"en","country":"US","source":{"id":"kite-timesargus-com-f2ab3d","name":"timesargus.com","domain":"timesargus.com","outlet":{"wikidata":"Q4863287","name":"Barre Montpelier Times Argus","type":"newspaper","country":"US","designations":["newspaper"]}},"via":"kite-timesargus-com-f2ab3d","topics":["vermont"],"authors":["Business Wire"],"entities":[{"id":"Q899140","name":"Genentech","type":"org"},{"id":"Q140876515","name":"European Society of Retina Specialists","type":"event"}],"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.36,"category2":"science-technology","sentiment":"positive","tone":0.38,"political":0.08},{"id":"n_2qi5vesxh4yaaavgzvjq","seq":1065275,"kind":"press_release","title":"Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions","url":"https://www.globenewswire.com/news-release/2026/10/01/3372533/0/en/roche-presents-new-data-at-euretina-highlighting-vabysmo-s-real-world-effectiveness-and-safety-across-major-retinal-conditions.html","summary":"Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). 1-3 Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust…","published":"2026-10-01T06:00:00Z","seen":"2026-10-01T06:15:39Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","swx:ro","otc markets:rhhby","swx:rog","ch0012032113","us7711951043","ch0012032048","9014"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q140876515","name":"European Society of Retina Specialists","type":"org"}],"mentions":2,"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.55,"sentiment":"positive","tone":0.39,"political":0.07}]}